Clinical Trial Update: Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment. [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating combination chemotherapy with or without bortezomib in patients with recurrent or refractory classical Hodgkin lymphoma; trial complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2020-04-20